| |
[摘要]：The HER2/NEU/erbB-2 oncogenic protein is a well-defined tumor-associated antigen that is overexpressed in several cancers, including breast and prostate cancers. A new vaccine candidate from Apthera, NeuVax (TM), consists of the HER2/NEU-derived immunogenic peptide E75, which induces a peptide-specific cytotoxic T-lymphocyte (CTL)-mediated immune response following intradermal administration. Clinical investigations to date hove shown that the E75 vaccine plus granulocyte-macrophage colony-stimulating factor (CM-CSF) as adjuvant reduces recurrence rates in breast and prostate cancer patients, with minimal toxicity. |
|
